Table 1
Modified WOMAC Questionnaire. Subjects responded with the following numerical assessment: 0 = none; 1 = slight; 2 = moderate; 3 = severe; 4 = extreme.

WOMAC A: Pain on
-
walking
-
stair climbing
-
nocturnal
-
rest
-
weight bearing
WOMAC B: Stiffness
-
morning
-
during the day
WOMAC C: Physical Functions
-
descending stairs
-
ascending stairs
-
rising from sitting
-
standing
-
bending to the floor
-
walking on flat
-
getting in/out of a car
-
going shopping
-
putting on socks
-
taking off socks
-
lying on bed
-
getting in/out of bath
-
sitting
-
getting out of toilet
-
heavy domestic duties
-
light domestic duties
Table 2
Response Rates of Patients to Treatments Based on Pain Assessments
4 weeks 12 weeks
| Criteria |
Flex Connect Plus/Placebo (n = 29) (n = 31) |
Flex Connect Plus/Placebo (n = 29) (n = 31) |
|
20% decrease in WOMAC pain |
69.2% 28.6% | 95.6% 29.8% |
Percentage of patients meeting various criteria for response to treatment. Results between the placebo (n
=
31) and Flex Connect Plus and MSM with Vitamin C were significantly different.
Table 3
Baseline characteristics of treatment groups.
| Flex Connect Plus MSM Vitamin C | Placebo | |
| N started (completed) | 29 (26) | 31 (29) |
| Age (years) | 53.6 +/− 1.2 | 52.3 +/− 1.8 |
| Gender (F:M %) | 58:32 | 70:30 |
|
Kellegren Lawrance Criteria Grade 2:3 % |
82:18 | 76:24 |
| WOMAC Pain | 8.8 +/− 0.3 | 9.1 +/− 0.3 |
| WOMAC Stiffness | 42 +/− 0.3 | 44 +/− 0.5 |
| WOMAC Function | 29.6 +/− 3.1 | 33.1 +/− 0.3 |
| WOMAC Total | 80.40 | 86.20 |
| VAS Pain | 61.3 +/− 0.6 | 60.9 +/− 0.3 |
Data expressed as percentage of total mean +/− SEM. The entry assessments between the Flex Connect Plus and MSM with Vitamin C, and placebo group were not significantly different.
Table 4
Laboratory
Evaluation
| Test | Flex Connect Plus & MSM with Vitamin C |
Flex-Connect WK 12 |
Placebo WK 0 |
Placebo WK 12 |
| Neutrophils % | 63.3 +/−1.7 | 63.12 +/− 1.2 | 62.16 +/− 1.9 | 62.46 +/− 1.2 |
| Lymphocytes % | 32.6 +/− 0.14 | 33.8 +/− 0.15 | 31.6 +/− 2.5 | 32.3 +/− 1.6 |
| Monocytes % | 1.16 +/− 0.3 | 1.21 +/− 0.14 | 1.11 +/− 0.11 | 1.12 +/− 1.6 |
| Eosinophils % | 3.44 +/− 0.41 | 3.21 +/− 0.26 | 3.46 +/− 0.11 | 3.11 +/− 1.6 |
| WBC mm3 | 7932 +/− 231 | 8031 +/− 144 | 8026 +/− 645 | 8011 +/− 298 |
| RBC mm3 | 3.96 +/− 0.08 | 4.11 +/− 0.11 | 3.96 +/− .11 | 3.98 +/− 0.08 |
| Hemoglobin gm/dl | 12.1 +/− 0.3 | 12.4 +/− 0.2 | 12.4 +/− 0.3 | 12.1 +/− 0.2 |
| Erythrocyte Sedimentation Rate | 33.2 +/− 4.2 | 30.6 +/− 3.0 | 29 +/− 3.6 | 31.2 +/− 1.2 |
| SGPT Iu/l | 28.7 +/− 1.8 | 27.6 +/− 2.3 | 29.1 +/− 1.3 | 29 +/− 1.6 |
| Creatinine | 0.98 +/− 0.03 | .94 +/− 0.03 | 1.3 +/− 0.3 | 1.2 +/− 0.2 |
Data Expressed as mean +/− SEM
Figure 1
Disposition of Study Patients

Figure 2
Responders % WOMAC Pain

-
Flex-Connect Plus with MSM Vitamin C
Placebo
Figure 3
WOMAC: Pain

-
Flex-Connect Plus with MSM Vitamin C
Placebo
Figure 4
WOMAC: Joint Stiffness

-
Flex-Connect Plus with MSM Vitamin C
Placebo
Figure 5
WOMAC: Physical Function

-
Flex-Connect Plus with MSM Vitamin C
Placebo
Figure 6
VSA Pain

-
Flex-Connect Plus with MSM Vitamin C










0 Comments